Black Diamond Therapeutics, Inc.
BDTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001701541
No open-market purchases or sales by Black Diamond Therapeutics, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $64.9M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Black Diamond Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 91
- −3 vs. Q2 2025
- Shares held
- 38.8M
- +164.3K (+0.4%) vs. Q2 2025
- Total value
- $147.0M
- +$51.2M (+53.5%) vs. Q2 2025
- New holders
- 21
- 28 more added
- Sold out
- 24
- 23 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BDTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 96 | $64.9M |
| Q1 2026 | 104 | $82.0M |
| Q4 2025 | 104 | $92.0M |
| Q3 2025 | 91 | $147.0M |
| Q2 2025 | 94 | $95.8M |
| Q1 2025 | 85 | $63.0M |
| Q4 2024 | 88 | $102.5M |
| Q3 2024 | 96 | $211.9M |
| Q2 2024 | 90 | $217.9M |
| Q1 2024 | 88 | $199.9M |
| Q4 2023 | 76 | $107.1M |
| Q3 2023 | 73 | $106.8M |
| Q2 2023 | 74 | $209.2M |
| Q1 2023 | 50 | $40.6M |
| Q4 2022 | 59 | $37.9M |
| Q3 2022 | 69 | $36.3M |
| Q2 2022 | 74 | $52.9M |
| Q1 2022 | 87 | $63.5M |
| Q4 2021 | 95 | $123.7M |
| Q3 2021 | 101 | $206.3M |
| Q2 2021 | 102 | $309.6M |
| Q1 2021 | 113 | $705.5M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Black Diamond Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bailard, Inc. | 0 | $0 | 0.00% | −15,800−100.0% | Sold out |
| Mercer Global Advisors Inc | 0 | $0 | 0.00% | −14,521−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −14,521−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −13,065−100.0% | Sold out |
| Wealth Enhancement Advisory Services, LLC | 0 | $0 | 0.00% | −10,984−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −10,440−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −10,250−100.0% | Sold out |
| Cerity Partners LLC | 0 | $0 | 0.00% | −10,299−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −10,139−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −2,186−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −398−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −335−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −183−100.0% | Sold out |
| Essential Partners LLC | 0 | $0 | 0.00% | −43−100.0% | Sold out |
| Mid-American Wealth Advisory Group, Inc. | 0 | $0 | 0.00% | −19−100.0% | Sold out |